Patients with Very High Risk of Cardiovascular Adverse Events during Carfilzomib Therapy: Prevention and Management of Events in a Single Center Experience

Patients with Very High Risk of Cardiovascular Adverse Events during Carfilzomib Therapy: Prevention and Management of Events in a Single Center Experience

Carfilzomib (CFZ) improves the prognosis of multiple myeloma (MM) patients but has shown cardiovascular toxicity. The risk stratification of cardiovascular adverse events (CVAEs) now seems well established, while little is known about the course and management of patients with a high-cardiovascular-...

Full description

Bibliographic Details
Main Authors: Giulia Mingrone, Anna Astarita, Anna Colomba, Cinzia Catarinella, Marco Cesareo, Lorenzo Airale, Arianna Paladino, Dario Leone, Fabrizio Vallelonga, Sara Bringhen, Francesca Gay, Franco Veglio, Alberto Milan
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Cancers
Subjects:
cardiovascular toxicity
multiple myeloma
carfilzomib
cardiovascular adverse event
arterial hypertension
echocardiography
Online Access:https://www.mdpi.com/2072-6694/15/4/1149

Internet

https://www.mdpi.com/2072-6694/15/4/1149

Similar Items